NEW YORK, May 26, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
Risk Evaluation and Mitigation Strategy (REMS) – Opioids,
Erythropoesis-Stimulating Agents and Cancer Therapeutics are the
Most Important Classes That Require REMS
http://www.reportlinker.com/p0512131/Risk-Evaluation-and-Mitigation-Strategy-REMS—Opioids-Erythropoesis-Stimulating-Agents-and-Cancer-Therapeutics-are-the-Most-Important-Classes-That-Require-REMS.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Risk Evaluation and Mitigation Strategy (REMS) – Opioids,
Erythropoesis-Stimulating Agents and Cancer Therapeutics are the
Most Important Classes That Require REMS
Summary
GBI Research’s research, “Risk Evaluation and Mitigation
Strategy (REMS) – Opioids, Erythropoesis-Stimulating Agents and
Cancer Therapeutics are the Most Important Classes That Require
REMS”, provides key data, information and analysis on the risk
management and mitigation strategies, mandated by the FDA and being
implemented by pharmaceutical companies. The report provides
information on the Risk Evaluation and Mitigation Strategies
(REMS), the reasons why companies implement REMS and the importance
of REMS. This report provides comprehensive analysis of REMS
approved up to date, components of REMS and safety
‘/>”/>
SOURCE
